IDH1 and central nervous system neoplasm: The 2016 WHO Classification of CNS Tumors introduced molecular criteria for classification and divided GBMs into isocitrate dehydrogenase-wildtype (IDH-wt), previously classified as primary GBM (about 90%), and IDH-mutant GBM, previously secondary GBM (about 10%) (1).